Ravindran A V, Charbonneau Y, Zaharia M D, al-Zaid K, Wiens A, Anisman H
Department of Psychiatry, University of Ottawa, Ont.
J Psychiatry Neurosci. 1998 Nov;23(5):288-92.
Currently, there is no documentation of the efficacy of venlafaxine (a serotonin norepinephrine reuptake inhibitor) in the treatment of dysthymia. This open-label pilot investigation examined the efficacy and tolerability of venlafaxine in patients with primary dysthymia without concomitant major depression.
Fifteen patients were treated with venlafaxine for 12 weeks, with a dose range of 75 mg to 225 mg daily (taken orally), and symptom changes were measured using standard instruments including the Hamilton Depression Rating Scale (HAM-D).
Significant changes from pretreatment to posttreatment were observed (p < 0.001). Using the standard criteria of a 50% reduction in HAM-D scores, 73.3% of patients were rated as responders. About two-thirds of the patients reported adverse events, which were mostly mild and brief in duration.
Venlafaxine may be useful in the treatment of primary dysthymia but placebo-controlled studies are required for confirmation.
目前，尚无文记载文拉法辛（一种5-羟色胺去甲肾上腺素再摄取抑制剂）治疗心境恶劣障碍的疗效。这项开放性试点研究考察了文拉法辛治疗无伴发重度抑郁的原发性心境恶劣障碍患者的疗效和耐受性。
15例患者接受文拉法辛治疗12周，剂量范围为每日75毫克至225毫克（口服），并使用包括汉密尔顿抑郁量表（HAM-D）在内的标准工具测量症状变化。
观察到从治疗前到治疗后有显著变化（p<0.001）。根据HAM-D评分降低50%的标准，73.3%的患者被评为有反应者。约三分之二的患者报告了不良事件，这些事件大多为轻度且持续时间短暂。
文拉法辛可能对原发性心境恶劣障碍的治疗有用，但需要进行安慰剂对照研究以证实。
